Distinct classes of fibroblasts in tumors play opposing roles, promoting or restraining pancreatic cancer growth

Researchers at The University of Texas MD Anderson Cancer Center have discovered that two distinct classes of cancer-associated fibroblasts (CAFs) accumulate in the pancreatic tumor microenvironment and play opposing roles to promote and restrain pancreatic cancer development.   The preclinical findings suggest that appropriately targeting these unique CAF populations may offer strategies to improve the use of other treatments, such as chemotherapy and immunotherapy.   “Cancer-associated fibroblasts are known to regulate cancer progression, but targeting these cells in pancreatic cancer has largely...

UTMB scientists develop a vaccine against Nipah virus

Scientists at the University of Texas Medical Branch have developed a vaccine showing promising protection against the Nipah virus, a zoonotic virus that has a mortality rate as high as 70 percent and that is considered to be a pathogen of pandemic potential.   Scientists working in the Biosafety Level 4 Lab at the Galveston National Laboratory developed the rapid-acting vaccine using a harmless recombinant Vesicular stomatitis virus vector to deliver a piece of the Nipah...

Inspired students make intubation more intuitive

Rice University bioengineering students are making a critical procedure easier for airway managers and safer for patients with a simplified, high-tech intubation device.   The Gateway to Airway team at Rice, working with an anesthesiologist, has developed a sleek laryngoscope that simplifies intubating patients for scheduled or emergent procedures.   The handheld, 3D-printed device contains a miniature wireless camera. Clinicians can use a switch on the comfortable handle to adjust the light from an LED near the camera, which...

Study defines stem cell groups that drive myelodysplastic syndromes, finds potential targeted therapy option

Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) is caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells. Their findings could have significant benefits for patients with disease progression. This research, which spans preclinical and clinical studies, represents the largest analysis to date of MDS patient samples. If further validated in larger clinical trials, the data...

COVID-19 variants can’t hide from Variabel

Details about variants hiding in the deluge of genetic SARS-CoV-2 sequences would be good to know, if only researchers a new program developed by Rice University’s George R. Brown School of Engineering will make it possible, at least for “intrahost variants,” those that appear in genome data from the same COVID-19-positive person. A Rice team led by computer scientist Todd Treangen and graduate student Yunxi Liu has developed Variabel, which accurately identifies “low-frequency variants” of the virus that causes COVID-19....

Targeting B7-H3 is a potential immunotherapy approach for high-risk AML

Acute myeloid leukemia (AML) is the most common leukemia in adults and, despite advances in targeted therapies, is associated with poor prognoses. Immunotherapy has shown promise, especially in combination with chemotherapy. A research team led by V. Lokesh Battula, Ph.D., demonstrated that the immune checkpoint protein B7-H3 may serve as a potential immunotherapy target in patients with AML. The team found elevated expression of B7-H3 to be associated with poor treatment outcomes in patients with AML. In preclinical studies,...

Antibody with engineered peptide targets bone metastasis

A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone. A study by scientists at Rice University and Baylor College of Medicine demonstrated the effective treatment of such cancers in rodent models, bringing hope for new therapies to treat bone metastases. The open-access study advances techniques pioneered by Rice chemist Han Xiao and his co-author at Baylor, biologist Xiang Zhang. They discovered through extensive testing that...

Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma

A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for the treatment of low-grade serous ovarian carcinoma. The international, multi-center Phase II/III trial led by David Gershenson, M.D., professor of Gynecologic Oncology & Reproductive Medicine, is the first positive randomized clinical trial of any therapy to demonstrate significantly increased progression-free survival (PFS) and objective...

Study reveals HPV vaccine impact on anal cancer

In a new study, researchers found evidence that HPV vaccination is reducing the incidence of anal cancer among young adults in the US. Researchers at the University of Texas Medical Branch analyzed data from the US Cancer Statistics database from 2001 to 2018 to examine anal cancer incidences among different age groups and determine the potential impact of HPV vaccination. They found that cancer incidence among young adults 20 to 44 years of age began to rapidly and significantly decrease within...

Blood test helps predict who may benefit from lung cancer screening

A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer screening than the current U.S. recommendation, according to a study led by researchers from The University of Texas MD Anderson Cancer Center. A personalized lung cancer risk assessment, combining a blood test based on a four-marker protein panel developed at MD Anderson and an independent model (PLCOm2012) that accounts for smoking history, was more sensitive and...

MJH footer logo with red letters

Medical Journal – Houston is the leading source of healthcare business news. With extremely relevant content, late-breaking news and monthly exclusives from industry experts, MJH News has created a winning combination of must-read editorial that physicians and hospital executives eagerly anticipate month after month. MJH News is the resource that provides everything they need in one place, and it is a high honor that they rely upon Medical Journal – Houston to keep their practice or hospital on the cutting edge.

Archives